Trastuzumab

Dosage for Trastuzumab is highly individualized and is typically calculated based on the patient's body weight (mg/kg). Your oncologist (cancer doctor) will determine the exact schedule, which usually follows a 'loading dose' followed by 'maintenance doses.'

Adjuvant Treatment of HER2-Positive Breast Cancer

There are two primary schedules used in the adjuvant setting:

• Weekly Schedule: An initial loading dose of 4 mg/kg administered as a 90-minute IV infusion, followed by weekly maintenance doses of 2 mg/kg administered as 30-minute infusions for a total of 52 weeks.
• Three-Weekly Schedule: An initial loading dose of 8 mg/kg administered as a 90-minute IV infusion, followed by maintenance doses of 6 mg/kg every three weeks for a total of 52 weeks.

Metastatic Breast Cancer

• Loading Dose: 4 mg/kg IV infusion over 90 minutes.
• Maintenance Dose: 2 mg/kg IV infusion weekly until disease progression or unacceptable toxicity occurs.

Metastatic Gastric Cancer

• Loading Dose: 8 mg/kg IV infusion over 90 minutes.
• Maintenance Dose: 6 mg/kg IV infusion every three weeks until disease progression or unacceptable toxicity occurs.

The safety and effectiveness of Trastuzumab in pediatric patients (children and adolescents under 18 years of age) have not been established. Clinical trials for the primary indications (breast and gastric cancer) are conducted in adult populations. Therefore, Trastuzumab is not currently approved for pediatric use.

Renal Impairment

Formal studies of Trastuzumab in patients with renal (kidney) impairment have not been conducted. However, because monoclonal antibodies are not primarily cleared by the kidneys, dosage adjustments are generally not required for patients with mild to moderate renal insufficiency. Caution is advised in patients with severe renal impairment.

Hepatic Impairment

No formal studies have been conducted in patients with hepatic (liver) impairment. As Trastuzumab is metabolized via general protein degradation rather than hepatic enzymes (like CYP450), liver function typically does not dictate the starting dose. However, liver function is monitored throughout therapy to ensure overall patient health.

Elderly Patients

In clinical trials, the risk of cardiac toxicity (heart problems) was found to be higher in patients over the age of 65. While the dosage remains the same based on weight, elderly patients require more frequent monitoring of their heart function (LVEF assessments).

Trastuzumab is a specialized medication that must be administered by a healthcare professional in a clinical setting (hospital or infusion center) equipped to handle potential infusion reactions.

1. 1Administration: It is given as an intravenous (IV) infusion. It must NEVER be given as an IV push or bolus.
2. 2Observation Period: During the first infusion, you will be monitored for at least 90 minutes for signs of an infusion reaction (fever, chills, shortness of breath). For subsequent maintenance doses, the observation period may be reduced to 30-60 minutes if the first dose was well-tolerated.
3. 3Preparation: The medication is usually diluted in a bag of 0.9% Sodium Chloride. It should not be mixed with Dextrose solutions as this can cause the protein to clump (aggregate).
4. 4Storage: Vials are stored in the refrigerator at 2°C to 8°C (36°F to 46°F). Once reconstituted, the solution is stable for a limited time (usually 28 days if using BWFI, or 24 hours if using SWFI).

If you miss an appointment for your Trastuzumab infusion, contact your oncologist immediately to reschedule. If the missed dose is delayed by one week or less, the maintenance dose (2 mg/kg for weekly or 6 mg/kg for three-weekly) should be given as soon as possible. If the dose is delayed by more than one week, a new loading dose (4 mg/kg for weekly or 8 mg/kg for three-weekly) may be required to quickly bring the drug levels back to the therapeutic range.

There is no specific antidote for a Trastuzumab overdose. In clinical trials, single doses up to 500 mg have been administered without reaching a 'maximum tolerated dose.' However, an overdose could potentially increase the risk of severe side effects, particularly cardiac toxicity or severe infusion reactions. If an overdose is suspected, the patient should be closely monitored for signs of heart failure or respiratory distress.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust your schedule without medical guidance, as this could reduce the effectiveness of the treatment.

Most patients receiving Trastuzumab will experience some side effects. Many of these are manageable and decrease over time. Common side effects include:

• Infusion-Related Reactions: Up to 40% of patients experience a 'flu-like' syndrome during or shortly after the first infusion. Symptoms include fever, chills, nausea, and headache.
• Fatigue: A general feeling of tiredness or lack of energy that does not improve with rest.
• Gastrointestinal Issues: Mild to moderate diarrhea, nausea, and vomiting are common, especially when Trastuzumab is combined with chemotherapy.
• Musculoskeletal Pain: Aching in the joints (arthralgia) or muscles (myalgia).
• Cough and Upper Respiratory Infections: Increased susceptibility to the common cold or persistent dry cough.
• Insomnia: Difficulty falling or staying asleep.
• Rash: Mild skin redness or irritation.

• Anemia: A decrease in red blood cells, leading to pale skin and shortness of breath.
• Leukopenia: A decrease in white blood cells, which can increase the risk of infection.
• Peripheral Neuropathy: Tingling, numbness, or burning sensations in the hands and feet (more common when used with taxane chemotherapy).
• Edema: Swelling of the legs, ankles, or hands due to fluid retention.
• Dizziness: A feeling of lightheadedness or spinning.

• Severe Hypersensitivity: A rare but life-threatening allergic reaction (anaphylaxis).
• Paresis: Partial loss of voluntary movement or muscle weakness.
• Tachycardia: An abnormally rapid heart rate.
• Hepatotoxicity: Inflammation of the liver, characterized by yellowing of the skin or eyes (jaundice).

> Warning: Stop taking Trastuzumab and call your doctor or seek emergency care immediately if you experience any of the following:

1. 1Congestive Heart Failure (CHF): Trastuzumab can significantly weaken the heart muscle. Symptoms include extreme shortness of breath, a persistent cough with frothy pink mucus, sudden weight gain (more than 5 pounds in 24 hours), and severe swelling of the legs or abdomen.
2. 2Severe Infusion Reactions: If you experience swelling of the face or tongue, difficulty swallowing, or a sudden drop in blood pressure during the infusion.
3. 3Pulmonary Toxicity: Severe inflammation of the lungs (interstitial lung disease). Symptoms include sudden onset of severe shortness of breath at rest and low oxygen levels.
4. 4Neutropenic Sepsis: If you have a high fever (over 100.4°F), chills, and extreme weakness, it may indicate a dangerously low white blood cell count and a severe infection.

The most significant long-term concern with Trastuzumab is its effect on the heart. While many patients see an improvement in heart function after stopping the drug, some may develop permanent cardiomyopathy (weakened heart muscle). Patients who have received anthracyclines (like doxorubicin) in the past are at a higher risk for these long-term cardiac issues. Regular heart monitoring (every 3 months) is typically required for at least a year following the completion of therapy.

The FDA has issued several 'Black Box Warnings' for Trastuzumab, which are the most serious warnings used for prescription drugs:

• Cardiomyopathy: Trastuzumab can cause subclinical and clinical cardiac failure. The incidence is highest when used in combination with anthracycline-containing chemotherapy. Left Ventricular Ejection Fraction (LVEF) must be evaluated before and during treatment.
• Infusion Reactions and Pulmonary Toxicity: Severe and sometimes fatal infusion reactions and lung inflammation have occurred. Most fatal reactions occurred during or within 24 hours of the first infusion.
• Embryo-Fetal Toxicity: Exposure to Trastuzumab during pregnancy can result in oligohydramnios (insufficient amniotic fluid), which can lead to fatal lung delays and skeletal abnormalities in the fetus.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Early detection of side effects is crucial for successful management.

Trastuzumab is a potent biological therapy that requires careful clinical oversight. It is not a traditional chemotherapy but a targeted antibody. Patients must be aware that while it is highly effective, it carries risks that necessitate frequent medical check-ups and laboratory testing. It is vital to disclose your entire medical history, especially any history of heart disease, high blood pressure, or lung conditions, to your oncologist before beginning treatment.

As mandated by the FDA, Trastuzumab carries the following boxed warnings:

1. 1Cardiomyopathy: Trastuzumab administration can result in ventricular dysfunction and congestive heart failure. Patients must undergo LVEF testing (via ECHO or MUGA scan) at baseline, every 3 months during therapy, and upon completion of therapy.
2. 2Infusion Reactions: Severe reactions, including bronchospasm (tightening of the airways), hypoxia (low oxygen), and severe hypotension (low blood pressure), can occur. Infusions must be discontinued for severe reactions.
3. 3Pulmonary Toxicity: This can manifest as interstitial pneumonitis or acute respiratory distress syndrome (ARDS). It is often most severe in patients with pre-existing lung disease or those whose cancer has spread to the lungs.
4. 4Embryo-Fetal Toxicity: This drug can cause fetal harm. Effective contraception is required for females of reproductive potential during treatment and for 7 months after the last dose.

Allergic Reactions / Anaphylaxis Risk

While most infusion reactions are mild, true anaphylaxis can occur. Patients with a known hypersensitivity to Trastuzumab, Chinese Hamster Ovary (CHO) cell proteins, or any component of the formulation should not receive the drug. If a severe reaction occurs, the infusion must be stopped immediately and emergency medications (like epinephrine and steroids) administered.

Cardiotoxicity

The risk of heart failure is cumulative. This means the risk may increase the longer you are on the drug or if you have other risk factors like uncontrolled high blood pressure. Your doctor may pause or permanently stop Trastuzumab if your LVEF drops by a certain percentage (usually a drop of 10% or more from baseline to a level below 50%).

Pulmonary Risks

Patients who are experiencing shortness of breath at rest due to complications of advanced cancer or other comorbidities may be at increased risk of fatal infusion reactions. These patients should be treated with extreme caution.

To ensure safety, your healthcare team will perform the following:

• LVEF Assessment: An echocardiogram (ECHO) or Multi-Gated Acquisition (MUGA) scan before the first dose and every 12 weeks during treatment.
• Complete Blood Count (CBC): To monitor for neutropenia (low white blood cells), especially when Trastuzumab is used with chemotherapy.
• Physical Exams: To check for signs of fluid retention or heart rhythm changes.

Trastuzumab generally does not cause significant impairment of the ability to drive or operate machinery. However, because it can cause dizziness or fatigue in some patients, you should wait to see how the medication affects you before engaging in these activities.

There is no known direct interaction between alcohol and Trastuzumab. However, alcohol can cause dehydration and may worsen certain side effects like nausea or fatigue. It is best to limit alcohol consumption during cancer treatment to support overall liver and heart health.

Trastuzumab does not cause physical dependence, and there is no 'withdrawal syndrome' associated with stopping it. However, stopping the drug prematurely in the adjuvant setting may increase the risk of cancer recurrence. In the metastatic setting, stopping the drug may allow the cancer to grow or spread. Always discuss the risks and benefits of discontinuation with your oncologist.

> Important: Discuss all your medical conditions, including any history of heart, lung, or kidney disease, with your healthcare provider before starting Trastuzumab.

There are no drugs that are strictly 'contraindicated' in the sense of causing an immediate chemical incompatibility in the body, but there are combinations that are avoided due to extreme toxicity risk:

• Anthracyclines (e.g., Doxorubicin, Epirubicin) and Trastuzumab simultaneously: While these drugs are often used sequentially (one after the other), using them at the same time is generally avoided. The combination significantly increases the risk of severe, irreversible heart failure. The mechanism is synergistic cardiotoxicity, where both drugs damage the heart muscle cells through different pathways.

• Anthracycline-based therapy (Sequential): Even if you finished taking doxorubicin months ago, the 'memory' of that drug remains in the heart tissue. The risk of cardiotoxicity with Trastuzumab remains elevated for up to 7 months after stopping anthracyclines due to the long half-life of both agents.
• Paclitaxel and Docetaxel: When used together with Trastuzumab, there may be a slight increase in the concentration of Trastuzumab in the blood. While this is the standard of care for many HER2+ cancers, it requires close monitoring for increased side effects like neutropenia (low white blood cells).
• Cyclophosphamide: Similar to anthracyclines, this chemotherapy agent can stress the heart, and its use in a regimen containing Trastuzumab requires vigilant LVEF monitoring.

• Warfarin or Blood Thinners: Trastuzumab does not directly interact with the metabolism of warfarin, but the potential for Trastuzumab to cause low platelet counts (thrombocytopenia) or liver irritation can indirectly increase the risk of bleeding. Close monitoring of the INR (International Normalized Ratio) is recommended.
• Belimumab: There is a theoretical risk that combining two monoclonal antibodies could alter the immune response or increase the risk of infection.

• Grapefruit and Grapefruit Juice: Unlike many small-molecule drugs, Trastuzumab is not metabolized by the CYP3A4 enzyme in the liver. Therefore, grapefruit does not significantly affect its levels. However, maintaining a healthy, balanced diet is recommended during cancer therapy.
• High-Fat Meals: Since Trastuzumab is administered intravenously, food intake does not affect its absorption or bioavailability.

• St. John's Wort: This herb is a potent inducer of liver enzymes. While it is unlikely to affect Trastuzumab levels directly, it can significantly lower the levels of many chemotherapy drugs often given alongside Trastuzumab, potentially reducing the overall effectiveness of your cancer treatment.
• Antioxidant Supplements (e.g., High-dose Vitamin E, Vitamin C): Some oncologists advise against high-dose antioxidants during active chemotherapy or targeted therapy, as they may theoretically interfere with the oxidative mechanisms used by some treatments to kill cancer cells. Always consult your doctor before starting any supplement.

• HER2 Testing: If you are currently receiving Trastuzumab, it may interfere with certain laboratory tests used to detect HER2 protein levels in new tissue samples, potentially leading to false results. Always inform the pathologist if you are on Trastuzumab therapy.
• Serum Digoxin: In rare cases, monoclonal antibodies might interfere with the assays used to measure digoxin levels. If you are taking heart medication, your doctor will monitor your levels closely.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes over-the-counter vitamins and 'natural' remedies, as they can impact your overall treatment safety.

Trastuzumab should never be used in the following circumstances:

1. 1Severe Hypersensitivity: Patients with a known, documented life-threatening allergic reaction to Trastuzumab or any of its excipients (the inactive ingredients). This includes reactions to Chinese Hamster Ovary (CHO) cell proteins, which are used in the manufacturing process of the antibody.
2. 2Severe Cardiac Failure at Baseline: If a patient already has symptomatic congestive heart failure or an LVEF of less than 40-45% before starting treatment, the risk of fatal cardiac collapse usually outweighs the potential benefits of the drug.

These are conditions where the doctor must carefully weigh the risk of treatment against the potential benefit:

• Pre-existing Lung Disease: Patients with conditions like COPD or pulmonary fibrosis are at a much higher risk for severe pulmonary toxicity and fatal infusion reactions.
• Uncontrolled Hypertension: High blood pressure puts additional strain on the heart. It must be brought under control with medication before and during Trastuzumab therapy to minimize the risk of heart failure.
• Prior Anthracycline Use: If you have received high cumulative doses of doxorubicin or epirubicin in the past, your heart's 'reserve' is lower, making Trastuzumab use more dangerous.
• Active Infection: While not a strict contraindication, doctors usually prefer to resolve any active, serious infections before administering a drug that can occasionally lower white blood cell counts.

Patients who have had reactions to other monoclonal antibodies (such as Rituximab or Pertuzumab) may be at a slightly higher risk for a reaction to Trastuzumab, although they are different molecules. There is no direct cross-reactivity documented, but the 'humanized' nature of these antibodies means the body's immune system is already primed to recognize similar protein structures. Always inform your nurse if you have reacted to any 'mab' (monoclonal antibody) drug in the past.

> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung function tests, before prescribing Trastuzumab to ensure it is safe for you.

Trastuzumab is associated with significant risks during pregnancy. It is classified as having high embryo-fetal toxicity.

• Oligohydramnios: Clinical data shows that use during pregnancy can lead to a lack of amniotic fluid. This is critical because amniotic fluid is necessary for the development of the fetus's lungs and kidneys.
• Fetal Harm: Cases of fetal renal failure, skeletal deformities, and neonatal death have been reported.
• Contraception: Women of childbearing age must use effective contraception during treatment and for at least 7 months after the final dose, as the drug stays in the system for a long time.
• Pregnancy Testing: A pregnancy test must be verified as negative before starting Trastuzumab.

It is not known whether Trastuzumab is excreted in human breast milk. However, because human IgG (the type of protein Trastuzumab is) is secreted in milk and there is a potential for serious adverse reactions in the nursing infant, women are advised to discontinue breastfeeding during treatment and for 7 months after the last dose. The long half-life of the drug means it remains in the body long after the final infusion.

Trastuzumab is not approved for use in children. The conditions it treats (HER2+ breast and gastric cancer) are almost exclusively adult diseases. There is no data on how this drug affects growth, development, or the immature immune systems of children. If a pediatric patient has a rare HER2-positive tumor, treatment would only occur within the context of a highly specialized clinical trial.

Patients aged 65 and older are at a significantly higher risk of developing Trastuzumab-induced heart failure compared to younger patients. In clinical trials, the risk of a significant drop in LVEF was nearly double in the elderly population. While the drug is still used in this age group because of its life-saving potential, cardiac monitoring is performed with even greater frequency and caution. There are no specific dosage changes required based solely on age, but the patient's overall 'frailty' and existing heart health are key factors.

No specific studies have been conducted in patients with kidney disease. However, because Trastuzumab is a large protein, it is not filtered by the kidneys in the same way small drugs are. Pharmacokinetic modeling suggests that mild to moderate renal impairment does not significantly change the drug's levels in the blood. No dose adjustment is typically recommended for these patients.

Trastuzumab has not been studied in patients with significant liver disease. Since the drug is broken down by general cellular processes rather than the liver's metabolic enzymes, it is generally considered safe to use at standard doses in patients with mild liver dysfunction. However, if a patient has severe hepatic impairment, the oncologist will monitor liver enzymes (ALT, AST, Bilirubin) closely during treatment.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.

Trastuzumab is a humanized IgG1 kappa monoclonal antibody that binds with high affinity (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). The HER2 gene (also known as ERBB2) encodes a transmembrane receptor tyrosine kinase. When Trastuzumab binds to this receptor, it prevents the homodimerization and heterodimerization of HER2 with other HER receptors (like HER3). This blocking action inhibits the downstream signaling of the PI3K/Akt pathway, which is responsible for cell survival, and the MAPK pathway, which drives cell proliferation. Furthermore, the Fc portion of the Trastuzumab antibody recruits Natural Killer (NK) cells to the tumor site, inducing Antibody-Dependent Cellular Cytotoxicity (ADCC).

The pharmacodynamics of Trastuzumab are centered on its ability to arrest the cell cycle in the G1 phase. It also reduces the expression of vascular endothelial growth factor (VEGF), which inhibits the tumor's ability to grow new blood vessels. There is a clear dose-response relationship; maintaining serum trough concentrations above 20 mcg/mL is generally associated with optimal therapeutic outcomes in metastatic breast cancer. Tolerance (the drug becoming less effective over time) can occur if the cancer cells develop alternative signaling pathways to bypass the blocked HER2 receptor.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); ~77% (SC) |

| Protein Binding | Minimal (it is a protein itself) |

| Half-life | ~28 days (range 1-32 days) |

| Tmax | End of infusion (IV); 3-7 days (SC) |

| Metabolism | Non-specific proteolytic degradation |

| Excretion | Reticuloendothelial system |

Trastuzumab is a large, complex protein with a molecular weight of approximately 148,000 Daltons. Its molecular formula is C6460H9972N1724O2014S44. It consists of two antigen-binding fragments (Fab) linked to a constant region (Fc). The antibody is produced in a mammalian cell culture (Chinese Hamster Ovary cells) and is purified using affinity and ion-exchange chromatography. It is highly soluble in water-based buffers but sensitive to agitation and extreme temperatures, which can cause denaturation (unfolding) of the protein.

Trastuzumab is the prototype of the HER2/neu receptor antagonist class. It is often grouped with other HER2-targeted therapies such as Pertuzumab (which binds to a different part of the HER2 receptor), Ado-trastuzumab emtansine (an antibody-drug conjugate), and Lapatinib (a small-molecule tyrosine kinase inhibitor). Within the EPC classification, it may also be listed as an Endoglycosidase when referring to specific glycoengineered biosimilar versions.